Intra nasal vaccines are easier to administer in mass immunization campaigns and can also help in stopping the transmission of the virus. The trials for 0.5 ml single dose of nasal vaccine will be conducted at nine locations in the country.
Bharat Biotech on Friday received approval from Drugs Controller General of India (DCGI) to conduct phase 3 clinical trials for its BBV 154 Nasal COVID vaccine. The trials will evaluate the efficacy of nasal vaccine for those vaccinated with the primary two doses of COVID vaccines (Covishield and Covaxin). Intra nasal vaccines are easier to administer in mass immunization campaigns and can also help in stopping the transmission of the virus. The trials for 0.5 ml single dose of nasal vaccine will be conducted at nine locations in the country. Hyderabad-based Bharat Biotech had asked for DCGI
